Syntis Bio launches oral therapies for metabolic diseases [Yahoo! Finance]
Codexis, Inc. (CDXS)
Last codexis, inc. earnings: 2/27 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.codexis.com/investors
Company Research
Source: Yahoo! Finance
diseases, from obesity to rare conditions such as homocystinuria (HCU) and maple syrup urine disease (MSUD). By leveraging the small intestine's role in metabolic control, digestion and drug absorption, Syntis Bio is progressing with a portfolio of promising programmes. In 2023 the company secured $15.5m in a seed funding round from investors including Safar Partners, Touchdown Ventures, BOLD Capital Partners, Colorcon Ventures and Portal Innovations. The company's lead obesity programme, SYNT-101, is currently undergoing human trials, while other rare disease assets are moving towards investigational new drug (IND)-enabling studies. It is a once-a-day oral medication designed to replicate the effects of gastric bypass surgery by temporarily obstructing nutrient uptake in the duodenum, the small intestine's upper part. The drug aims to reroute nutrients to the lower small intestine, enhancing controlled absorption and triggering a series of satiety hormones such as GLP-1 and
Show less
Read more
Impact Snapshot
Event Time:
CDXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDXS alerts
High impacting Codexis, Inc. news events
Weekly update
A roundup of the hottest topics
CDXS
News
- Syntis Bio Launches to Revolutionize Oral Therapy for Obesity, Diabetes and Rare Diseases by Unlocking the Full Therapeutic Potential of the Small Intestine [Yahoo! Finance]Yahoo! Finance
- Codexis, Inc. (NASDAQ: CDXS) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $5.00 price target on the stock.MarketBeat
- Codexis, Inc. (NASDAQ: CDXS) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $11.00 price target on the stock.MarketBeat
- Codexis to Participate in Jefferies Global Healthcare ConferenceGlobeNewswire
- Global Industrial Enzymes Strategic Industry Report 2024-2030: Developing Countries Continue to Offer Significant Growth Opportunities [Yahoo! Finance]Yahoo! Finance
CDXS
Earnings
- 5/2/24 - Beat
CDXS
Sec Filings
- 6/13/24 - Form 4
- 6/13/24 - Form 4
- 6/13/24 - Form 4
- CDXS's page on the SEC website